Simulations Plus Inc Stock Price, News & Analysis

Simulations Plus (Nasdaq: SLP), a prominent provider of biosimulation and medical communications solutions for the biopharma industry, has announced a new research project with the International Collaboration on Cosmetics Safety (ICCS). The project aims to define best practices for using novel physiologically-based kinetic (PBK) modeling strategies to support animal-free safety assessments of new chemicals. Simulations Plus was selected through a competitive bidding process to establish workflows for PBK modeling based on pharmacokinetic analogs. The collaboration will involve reviewing ICCS data, building PBK models, and applying these in virtual populations to predict chemical exposure. Results and best practices will be published, potentially advancing non-animal testing methods in the cosmetics industry.

Simulations Plus (Nasdaq: SLP) reported its Q3 fiscal 2024 results, showing a 14% increase in total revenue to $18.5M. Software revenue rose 12% to $11.9M, and services revenue grew 18% to $6.6M. Despite consistent gross profit at $13.3M, net income declined to $3.1M from $4.0M, with diluted EPS dropping to $0.15 from $0.20. Adjusted diluted EPS, excluding acquisition costs, was $0.19. For the first nine months of fiscal 2024, total revenue increased 17% to $51.3M, with a net income of $9.1M and diluted EPS of $0.45. The company maintains FY2024 revenue guidance of $69-72M and updates EPS guidance.

The recent acquisition of Pro-ficiency is progressing as planned, and the newly formed Clinical Simulations and Medical Communications unit is expected to contribute $3M in FY2024. The company will discontinue its quarterly dividend to reallocate funds towards growth initiatives. A final dividend of $0.06 per share will be paid on August 5, 2024, to shareholders of record as of July 29, 2024.

Simulations Plus (Nasdaq: SLP), a leader in biosimulation and medical communications for the biopharma sector, announced CEO Shawn O’Connor's participation in the Morgan Stanley 3rd Annual Life Sciences AI Summit. The summit is scheduled for June 26, 2024, at Morgan Stanley's HQ in New York City. O’Connor will engage in a panel discussion titled “Transforming Research – Optimizing from Lab to Trial” at 2:10 p.m. EDT, followed by one-on-one meetings with investors. The event emphasizes AI-driven changes in the biopharma industry, featuring key companies at the juncture of life sciences and technology innovation.

Simulations Plus (Nasdaq: SLP) announced that it will release its third quarter fiscal 2024 financial results after market close on July 2, 2024. A conference call to discuss these results will be held at 5:00 p.m. EDT on the same day. The call is open to investment professionals and shareholders, who can join via webcast or by dialing in. The webcast will be available for replay on the Simulations Plus investor relations webpage about an hour after the call concludes.

QHP Capital has announced the sale of Pro-ficiency, a provider of tech-enabled training and compliance solutions for clinical trial investigators, to Simulations Plus (Nasdaq: SLP). Pro-ficiency has grown significantly since QHP's initial investment in 2021, completing acquisitions of Fugitive Labs in 2022 and Compass Group Partners in 2023.

Simulations Plus, a leader in modeling and simulation software and services for pharmaceutical safety and efficacy, views this acquisition as a strategic move to expand its market reach and enhance service offerings. Pro-ficiency's CEO, Michael Raymer, expressed enthusiasm about the merger, highlighting the complementary operations and aligned cultures of the two companies. Both teams are aiming to leverage each other's strengths to improve client performance and attract new customers with comprehensive solutions.

Simulations Plus (Nasdaq: SLP) has acquired Pro-ficiency Holdings for $100 million in cash, expanding its capabilities in drug development and commercialization. This acquisition doubles the company's total addressable market (TAM) to $8 billion and is expected to be accretive to fiscal 2025 EPS. The integration of Pro-ficiency’s simulation-enabled solutions enhances Simulations Plus' existing offerings, providing end-to-end services from pre-clinical protocols to product commercialization. The company will host a conference call to discuss the transaction.

Simulations Plus (Nasdaq: SLP), a leader in modeling and simulation solutions across various industries, will participate in the 21st Annual Craig-Hallum Institutional Investor Conference on May 29, 2024, in Minneapolis. CEO Shawn O'Connor will represent the company, engaging in one-on-one and small group meetings. This event features over 130 public companies, offering institutional clients the opportunity to meet with corporate management. Attendance is by invitation only.

Simulations Plus has launched GastroPlus® X (GPX™), marking a significant upgrade in PBPK/PBBM modeling and simulation software. This new platform offers advanced models, refined algorithms, and integrated machine learning, alongside an intuitive interface and streamlined workflows. GPX is designed to enhance productivity through ease-of-use and faster processing. The development involved extensive user testing and feedback, resulting in a flexible platform that supports diverse research needs. Notably, GPX includes unique features like true polypharmacy simulations and flexible deployment options, including cloud integration. Available for licensing now, GPX aims to expand Simulations Plus's global market reach.